Adherence to Secondary Prevention Guidelines for Cardiovascular Risk
1 other identifier
observational
129
1 country
1
Brief Summary
The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2024
CompletedFirst Submitted
Initial submission to the registry
June 3, 2024
CompletedFirst Posted
Study publicly available on registry
June 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2025
CompletedDecember 17, 2025
December 1, 2025
1.6 years
June 3, 2024
December 10, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge
Proportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL
Up to 3 months
Study Arms (1)
Patients hospitalized due to a cardiovascular event
Patients hospitalized due to a cardiovascular event including stroke, acute coronary syndrome, ischemic heart disease, or peripheral arterial disease
Interventions
In this single group observational trial the exposure of interest is a cardiovascular event.
Eligibility Criteria
Patients hospitalized due to a cardiovascular event
You may qualify if:
- Admitted to the cardiology, neurology, or general surgery departments
- With any of the following admission diagnoses:
- Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause
You may not qualify if:
- Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy
- Patients likely to die during hospitalization
- Patients who died during hospitalization
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Consorci Sanitari Alt Penedes i Garraf-Hospital Sant Camil
Sant Pere de Ribes, Barcelona, 08810, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lidia Tikhomirova
CSAPG
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 3, 2024
First Posted
June 10, 2024
Study Start
March 1, 2024
Primary Completion
September 30, 2025
Study Completion
September 30, 2025
Last Updated
December 17, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- After publication of main results of the study.
- Access Criteria
- IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).